Sodium channel blocker with potent anticonvulsant activity; potential for novel treatment for Schizophrenia. CNV 1014802 (GSK 1014802 or GSK2 or Raxatrigine) was tested in clinical trials for treatment of trigeminal neuralgia, and shows selectivity for the Nav1.7 subtype over the other subtypes tested (Nav1.1, Nav1.2, Nav1.3, Nav1.5, Nav1.6 and TTX-R), for both the resting and depolarized states.

The water soluble HCl salt of CNV 1014802 (Axon 2548) is available as well

KEYWORDS: CNV 1014802 | supplier | Na+ channel blocker | GSK 1014802 | GSK2 | Raxatrigine | BIIB 074 | Vixotrigine | CNV1014802 | CNV-1014802 | GSK1014802 | GSK-1014802 | GSK 2 | GSK-2 | BIIB074 | BIIB-074 | CAS [934240-30-9] | Sodium | Nav1.7 | Nav1.2 | Nav1.6 | Nav1.3 | Blocker | Ion Channels | anticonvulsant | Schizophrenia | trigeminal neuralgia | neuropathic | pain